• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    1/12/24 4:31:10 PM ET
    $ABSI
    $ACON
    $BCEL
    $BCLI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Medical Specialities
    Health Care
    Get the next $ABSI alert in real time by email

    Gainers

    • Aclarion (NASDAQ:ACON) stock rose 21.6% to $3.82 during Friday's after-market session. The company's market cap stands at $3.2 million.
    • Outset Medical (NASDAQ:OM) shares rose 10.61% to $4.95. The market value of their outstanding shares is at $248.5 million.
    • Absci (NASDAQ:ABSI) stock moved upwards by 9.77% to $4.38. The market value of their outstanding shares is at $407.0 million.
    • Processa Pharma (NASDAQ:PCSA) shares rose 8.71% to $0.29. The company's market cap stands at $7.0 million.
    • Cara Therapeutics (NASDAQ:CARA) stock increased by 7.94% to $0.62. The company's market cap stands at $33.5 million.
    • Monopar Therapeutics (NASDAQ:MNPR) shares moved upwards by 6.44% to $0.46. The market value of their outstanding shares is at $6.8 million.

    Losers

    • Atreca (NASDAQ:BCEL) stock decreased by 21.4% to $0.28 during Friday's after-market session. The market value of their outstanding shares is at $11.0 million.
    • Estrella Immunopharma (NASDAQ:ESLA) shares declined by 10.57% to $1.1. The market value of their outstanding shares is at $38.7 million.
    • Nektar Therapeutics (NASDAQ:NKTR) stock declined by 6.41% to $0.5. The market value of their outstanding shares is at $95.3 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares decreased by 5.17% to $0.31. The company's market cap stands at $15.1 million.
    • Context Therapeutics (NASDAQ:CNTX) shares fell 5.05% to $1.13. The company's market cap stands at $18.0 million.
    • Revelation Biosciences (NASDAQ:REVB) shares fell 5.03% to $0.45. The company's market cap stands at $2.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI
    $ACON
    $BCEL
    $BCLI

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    3/24/2026$70.00Neutral
    Wedbush
    Nektar Therapeutics
    $NKTR
    3/17/2026Buy
    TD Cowen
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Absci Corporation
    $ABSI
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    More analyst ratings

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Legal Officer Walker Shelby J. was granted 90,300 shares and covered exercise/tax liability with 9,825 shares, increasing direct ownership by 136% to 139,775 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:56:32 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: CFO / CBO Jonasson Zachariah was granted 135,400 shares and covered exercise/tax liability with 10,848 shares, increasing direct ownership by 33% to 499,783 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:55:34 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SVP, CAO Bedrick Todd was granted 49,600 shares and covered exercise/tax liability with 5,282 shares, increasing direct ownership by 26% to 216,942 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:53:54 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $229,000 worth of shares (100,000 units at $2.29), increasing direct ownership by 31% to 421,446 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/16/26 4:17:22 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Pangalos Menelas N bought $205,760 worth of shares (75,095 units at $2.74), increasing direct ownership by 66% to 189,055 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/3/26 4:13:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Nektar Therapeutics with a new price target

    Wedbush initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $70.00

    3/24/26 8:19:49 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Nektar Therapeutics

    TD Cowen initiated coverage of Nektar Therapeutics with a rating of Buy

    3/17/26 7:57:51 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

    Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported

    3/24/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic

    VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI,  announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic. Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an

    3/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    SEC Filings

    View All

    SEC Form S-8 filed by Absci Corporation

    S-8 - Absci Corp (0001672688) (Filer)

    3/24/26 4:52:15 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by Absci Corporation

    10-K - Absci Corp (0001672688) (Filer)

    3/24/26 4:30:46 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Absci Corp (0001672688) (Filer)

    3/24/26 4:28:17 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Financials

    Live finance-specific insights

    View All

    Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

    Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported

    3/24/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Leadership Updates

    Live Leadership Updates

    View All

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

    SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 Results Revenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024.Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more t

    1/12/26 8:30:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:31:29 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Context Therapeutics Inc.

    SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:05:15 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ACON
    $BCEL
    $BCLI
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care